MP
ACRS icon

MFN Partners’s Aclaris Therapeutics ACRS Stock Holding History

MFN Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,338,718
Closed -$5.41M – 17
2020
Q2 		$5.41M Sell
3,338,718
-661,282
-17% -$886K 0.75% 11
2020
Q1 		$4.16M Hold
4,000,000
– – 0.55% 15
2019
Q4 		$7.56M Buy
4,000,000
+2,500,000
+167% +$4.14M 1.56% 9
2019
Q3 		$1.62M Hold
1,500,000
– – 0.24% 13
2019
Q2 		$3.29M Hold
1,500,000
– – 0.52% 15
2019
Q1 		$8.98M Hold
1,500,000
– – 1.45% 13
2018
Q4 		$11.1M Buy
+1,500,000
New +$15.5M 1.88% 12

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFN Partners's ACRS Position: Q3 2020 in Review

MFN Partners sold out of Aclaris Therapeutics (ACRS) in Q3 2020, closing a stake of 3,338,718 shares — an estimated $5.41M sold.

MFN Partners first reported a position in ACRS in Q4 2018 and held it in 7 quarters. The position peaked at $11.1M in Q4 2018. 57 funds tracked by Wall St. Rank hold ACRS as of Q3 2020.

  • MFN Partners reported no remaining Aclaris Therapeutics position as of Q3 2020 after selling out during the quarter.
  • MFN Partners sold 3,338,718 Aclaris Therapeutics shares in Q3 2020, an estimated $5.41M.
  • MFN Partners first reported a position in Aclaris Therapeutics in Q4 2018 and held it in 7 quarters.
  • MFN Partners's Aclaris Therapeutics position peaked at $11.1M in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2020.

Based on MFN Partners's 13F filing for Q3 2020, filed 13 Nov 2020.